Analysis of effect isoxsuprine hydrochloride and nicotine in the Transverse Rectus Abdominis Myocutaneous flap (TRAM) in rats.
OBJECTIVE
To evaluate the effects of isoxsuprine and nicotine on TRAM.


METHODS
Forty eight 48 Wistar rats distributed into four Groups (n=12). All rats received medication managed daily for 20 days: saline solution (SA), nicotine solution (NI), isoxsuprine solution (IS) and nicotine solution (NI) + isoxsuprine solution (IS). On day 21st the rats were submitted to the caudally based, right unipedicled TRAM flap and after 48 hours, made the macroscopic evaluation of the surface of the flap, photographic documentation and collection of material for histology. Data from macroscopic evaluation were analyzed by ANOVA and microscopic evaluation by Kruskal-Wallis test, with significance level of 5%.


RESULTS
In the macroscopic evaluation of isoxsuprine Group retail presented absolute numbers: final area (p=0.001*) and viable area (p=0.006*) with the highest values; necrosis (p=0.001*) had the lowest value. Microscopic examination revealed no significant findings in the study of TRAM under the action of isoxsuprine and nicotine to the percentage of necrosis in the left and right cranial and caudal regions.


CONCLUSIONS
There was significant improvement in viability of TRAM using the isoxsuprine solution alone. No influence using nicotine alone and in association with isoxsuprine.
Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Walder
W
Costa
Department of Surgery, Faculty of Medicine, UFMG, Belo Horizonte, MG, Brazil.
Alcino Lázaro da
AL
Silva
Hospital Governador Israel Pinheiro, IPSEMG, Belo Horizonte, MG, Brazil.
Gustavo Rocha
GR
Costa
Department of Pathology and Forensic Medicine, Faculty of Medicine, UFMG, Belo Horizonte, MG, Brazil.
Paula Vieira Teixeira
PV
Vidigal
Faculty of Medicine, UFMG, Belo Horizonte, MG, Brazil.
Fernando Henrique
FH
Pereira
D000818:Animals; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D007556:Isoxsuprine / Q000494:pharmacology*; D023421:Models, Animal; D064827:Myocutaneous Flap / Q000473:pathology; D009336:Necrosis / Q000473:pathology; D009538:Nicotine / Q000009:adverse effects*; D018722:Nicotinic Agonists / Q000009:adverse effects*; D011446:Prospective Studies; D017208:Rats, Wistar; D017568:Rectus Abdominis / Q000187:drug effects / Q000473:pathology / Q000637:transplantation*; D015203:Reproducibility of Results; D012907:Smoking / Q000009:adverse effects; D014022:Tissue Survival / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
D018722:Nicotinic Agonists; D014665:Vasodilator Agents; D009538:Nicotine; D007556:Isoxsuprine